<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-88" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-88" data-turn-id-container="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-88" data-testid="conversation-turn-172" data-scroll-anchor="false" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="17c6280c-8b55-4432-ad56-afc28e846229" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/radiation-induced-oral-mucositis-in-prostate-cancer-market"><strong>Radiation Induced Oral Mucositis in Prostate Cancer</strong></a> is a radiation-associated inflammatory condition characterized by painful mucosal injury, ulceration, and tissue damage occurring as a consequence of radiotherapy exposure during prostate cancer treatment.</p>
<h3 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Cases of Prevalent Prostate Cancer</li>
<li dir="ltr" role="presentation">Radiotherapy Utilization in Prostate Cancer</li>
<li dir="ltr" role="presentation">Radiotherapy Modalities in Prostate Cancer</li>
<li dir="ltr" role="presentation">Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities</li>
</ul>
<h2 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">Total cases of prevalent prostate cancer in the 7MM were estimated at approximately 7.7 million in 2025.</li>
<li dir="ltr" role="presentation">Radiation-induced mucositis in prostate cancer among radiotherapy modalities in the 7MM accounted for nearly 1.1 million cases in 2025.</li>
<li dir="ltr" role="presentation">These cases are expected to grow at a CAGR of 1.6% by 2036.</li>
<li dir="ltr" role="presentation">In the United States, IMRT remains the most widely adopted and advanced radiotherapy modality in prostate cancer, accounting for approximately 390,000 treated cases in 2025.</li>
<li dir="ltr" role="presentation">Radiotherapy utilization in prostate cancer is highest in localized disease, accounting for nearly 270,000 cases in 2025 in the US, with cases expected to further increase during the forecast period.</li>
<li dir="ltr" role="presentation">Increasing prostate cancer incidence, broader radiotherapy adoption, and improving survivorship are contributing to the growing burden of radiation-induced mucositis across the 7MM.</li>
</ul>
<h2 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Radiation-Induced Oral Mucositis in Prostate Cancer market in the 7MM was valued at approximately USD 30 million in 2025.</li>
<li dir="ltr" role="presentation">The market is expected to grow at a CAGR of 9% during the forecast period from 2026 to 2036.</li>
<li dir="ltr" role="presentation">By 2036, the market is projected to nearly double, driven by rising prostate cancer prevalence, expanded radiotherapy utilization, increasing post-radiation survivorship, and the launch of emerging therapies.</li>
<li dir="ltr" role="presentation">In 2025, treatment spending across the 7MM remained heavily concentrated on suppository/enema therapies, accounting for nearly USD 15 million, followed by intravenous fluid therapies at approximately USD 6 million.</li>
<li dir="ltr" role="presentation">Currently, there are no approved pharmacologic therapies specifically indicated for radiation-induced mucositis in prostate cancer, and treatment largely remains supportive and symptom-based.</li>
</ul>
<h3 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising incidence of prostate cancer is increasing the utilization of radiotherapy and associated supportive care demand.</li>
<li dir="ltr" role="presentation">Growing awareness regarding GI/GU toxicities associated with radiation exposure is supporting earlier intervention and management strategies.</li>
<li dir="ltr" role="presentation">Development of cost-effective supportive care therapies and emerging treatment approaches is expected to drive future market growth.</li>
<li dir="ltr" role="presentation">Increasing focus on survivorship care and quality-of-life management is further expanding clinical attention toward radiation-induced toxicities.</li>
</ul>
<h3 dir="ltr"><strong>Radiation Induced Oral Mucositis in Prostate Cancer Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Lack of approved targeted pharmacologic therapies continues to limit effective disease management.</li>
<li dir="ltr" role="presentation">Limited real-world understanding of mucositis risk across various radiotherapy techniques restricts optimized preventive strategies.</li>
<li dir="ltr" role="presentation">Widely available low-cost supportive care products reduce pricing power and commercial incentives for innovation.</li>
<li dir="ltr" role="presentation">Challenges in predicting and preventing radiation-induced mucositis in high-risk patients continue to hinder treatment optimization.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Radiation Induced Oral Mucositis in Prostate Cancer Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">LP-10</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Radiation Induced Oral Mucositis in Prostate Cancer Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Lipella Pharmaceuticals</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
</div>
</div>
</div>
</div>
</div>
</div>
</section>
</div>
</div>